Expression of osteopontin and CD44 molecule in papillary renal cell tumors

Pathology and Oncology Research

Volumn 11, Issue 2, 2005, Pages 108-113

  Matusan, Koviljka ^a   Dordevic, Gordana ^a   Mozetic, Vladimir ^b   Lucin, Ksenija ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b KBC RIJEKA   (Croatia)

Author keywords

CD44s antigen; CD44v6 antigen; Cell adhesion; Immunohistochemistry; Osteopontin; Papillary renal cell carcinoma

Indexed keywords

CD44V6 ANTIGEN; KI 67 ANTIGEN; OSTEOPONTIN;

ARTICLE; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY ADENOMA; KIDNEY CARCINOMA; MALE; PAPILLARY CARCINOMA; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION;

EID: 22844440085     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893377     Document Type: Article

References (26)

1. Agrawal D, Chen T, Irby R, et al: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513-521, 2002
2. Amin MB, Corless CL, Renshaw AA, et al: Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 21:621-635, 1997
3. Ariztia EV, Subbarao V, Solt DB, et al: Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation. Exp Cell Res 288:257-267, 2003
4. Brown LF, Papadopoulos-Sergiou A, Berse B, et al: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610-623, 1994
5. Coppola D, Szabo M, Boulware D, et al: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histogenesis. Clin Cancer Res 10:184-190, 2004
6. Craig AM, Denhardt DT: The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene 100:163-171, 1991
7. Delahunt B, Eble JN: Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537-544, 1997
8. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: WHO Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. 6st vol. IARC Press, Lyon (France), 2004, pp: 9-87
9. Fuhrman S, Lasky L, Lumas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-663, 1982
10. Gilcrease MZ, Guzman-Paz M, Niehans G, et al: Correlation of CD44s expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 86:2320-2326, 1999
11. Glukhova L, Goguel AF, Chudoba I, et al: Overexpression of 7q31 and 17q in renal cell carcinoma. Genes Chromosomes Cancer 5:348-356, 1998
12. Guinan P, Sobin LH, Algaba F, et al: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80:992-993, 1997
13. Gunthert U, Stauder R, Mayer B, et al: CD44 variant isoforrns involved in human tumor progression? Cancer Surv 24:19-42, 1995
14. Guo X, Zhang YP, Mitchell DA, et al: Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol 15:476-487, 1995
15. Heider KH, Ratschek M, Zatloukal K, et al: Expression of CD44 isoforms in human renal cell carcinomas. Virchows Arch 428:267-273, 1996
16. Kovacs G, Fuzesi L, Emanual A, et al: Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer 3:249-255, 1991
17. Lubensky IA, Schmidt L, Zhuang Z, et al: Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155:517-526, 1999
18. Lucin K, Matusan K, Dordevic G, et al: The expression of osteopontin in renal cell carcinomas. In: Proceedings of the Second Intercontinental Congress of Pathology. (Eds: Soares F, Vassallo J, Torres LFB), Medimond, 2004, p: 151-154
19. Lucin K, Matusan K, Dordevic G, et al: Prognostic significance of CD44 molecule in renal cell carcinoma. Croat Med J 45:703-708, 2004
20. Oldberg A, Franzen A, Heinegard D: Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals and Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 83:8819-8823, 1986
21. Pan HW, Ou YH, Peng SY, et al: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119-127, 2003
22. Paradis V, Ferlicot S, Ghannam E, et al: CD44 is an independent prognostic factor in conventional renal cell carcinomas. J Urology 161:1984-1987, 1999
23. Rittling SR, Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90:1877-1881, 2004
24. Rudland PS, Platt-Higgins A, El-Tanani M, et al: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417-3427, 2002
25. Terpe HJ, Storkel S, Zimmer U, et al: Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol 148:453-463, 1996
26. Zbigniew R, Serge J: CD44 and the adhesion of neoplastic cells. J Clin Pathol: Mol Pathol 50:57-71, 1997